Literature DB >> 20068085

Analysis of genetic variants in never-smokers with lung cancer facilitated by an Internet-based blood collection protocol: a preliminary report.

Nicolas Girard1, Emil Lou, Christopher G Azzoli, Rekha Reddy, Mark Robson, Megan Harlan, Irene Orlow, Yasushi Yatabe, Khedoudja Nafa, Marc Ladanyi, Agnes Viale, Mark G Kris, Gregory Riely, Vincent Miller, Robert J Klein, Keitaro Matsuo, William Pao.   

Abstract

PURPOSE: Germ line polymorphisms may confer susceptibility to lung cancer in never smokers, but studies in the United States have been limited by the low number of cases seen at single institutions. We hypothesized that we could use the Internet to bolster the accrual of appropriate patients. EXPERIMENTAL
DESIGN: We established an Internet-based protocol to collect blood and information from patients throughout the United States. To illustrate the power of this approach, we used these samples, plus additional cases and age-matched controls from the Memorial Sloan-Kettering Cancer Center (New York, NY) and the Aichi Cancer Center (Nagoya, Japan), to analyze germ line DNA for genetic variants reportedly associated with lung cancer susceptibility. The genotypes for the polymorphisms rs763317 (intron 1) and T790M (exon 20) in the EGFR gene were determined by direct sequencing, and CHRNA3 nicotinic acetylcholine receptor single nucleotide polymorphisms (rs8034191 and rs1051730) were genotyped as part of a pilot genome-wide association study.
RESULTS: We successfully analyzed germ line DNA from 369 cases, including 45 obtained via the Internet, and 342 controls. A germ line EGFR T790M variant was identified in 2 of the 369 cases (0.54%; 95% confidence interval, 0.21-1.29%), and in none of the 292 controls (P = 0.21). No difference was observed in EGFR rs763317 frequency between cases and controls. Similarly, neither CHRNA3 rs8034191 nor rs1051730 were associated with lung cancer risk.
CONCLUSIONS: The Internet provides a way to recruit patients throughout the country for minimal risk studies. This approach could be used to facilitate studies of germ line polymorphisms in specific groups of patients with cancer.

Entities:  

Mesh:

Year:  2010        PMID: 20068085      PMCID: PMC2808124          DOI: 10.1158/1078-0432.CCR-09-2437

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  25 in total

1.  Secondhand smoke exposure in adulthood and risk of lung cancer among never smokers: a pooled analysis of two large studies.

Authors:  Paul Brennan; Patricia A Buffler; Peggy Reynolds; Anna H Wu; H Erich Wichmann; Antonio Agudo; Göran Pershagen; Karl-Heinz Jöckel; Simone Benhamou; Raymond S Greenberg; Franco Merletti; Carlos Winck; Elizabeth T H Fontham; Michaela Kreuzer; Sarah C Darby; Francesco Forastiere; Lorenzo Simonato; Paolo Boffetta
Journal:  Int J Cancer       Date:  2004-03       Impact factor: 7.396

2.  Radon in homes and risk of lung cancer: collaborative analysis of individual data from 13 European case-control studies.

Authors:  S Darby; D Hill; A Auvinen; J M Barros-Dios; H Baysson; F Bochicchio; H Deo; R Falk; F Forastiere; M Hakama; I Heid; L Kreienbrock; M Kreuzer; F Lagarde; I Mäkeläinen; C Muirhead; W Oberaigner; G Pershagen; A Ruano-Ravina; E Ruosteenoja; A Schaffrath Rosario; M Tirmarche; L Tomásek; E Whitley; H-E Wichmann; R Doll
Journal:  BMJ       Date:  2004-12-21

3.  Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1.

Authors:  Christopher I Amos; Xifeng Wu; Peter Broderick; Ivan P Gorlov; Jian Gu; Timothy Eisen; Qiong Dong; Qing Zhang; Xiangjun Gu; Jayaram Vijayakrishnan; Kate Sullivan; Athena Matakidou; Yufei Wang; Gordon Mills; Kimberly Doheny; Ya-Yu Tsai; Wei Vivien Chen; Sanjay Shete; Margaret R Spitz; Richard S Houlston
Journal:  Nat Genet       Date:  2008-04-02       Impact factor: 38.330

4.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

Authors:  Ross L Levine; Martha Wadleigh; Jan Cools; Benjamin L Ebert; Gerlinde Wernig; Brian J P Huntly; Titus J Boggon; Iwona Wlodarska; Jennifer J Clark; Sandra Moore; Jennifer Adelsperger; Sumin Koo; Jeffrey C Lee; Stacey Gabriel; Thomas Mercher; Alan D'Andrea; Stefan Fröhling; Konstanze Döhner; Peter Marynen; Peter Vandenberghe; Ruben A Mesa; Ayalew Tefferi; James D Griffin; Michael J Eck; William R Sellers; Matthew Meyerson; Todd R Golub; Stephanie J Lee; D Gary Gilliland
Journal:  Cancer Cell       Date:  2005-04       Impact factor: 31.743

Review 5.  Worldwide epidemiological patterns of lung cancer in nonsmokers.

Authors:  L C Koo; J H Ho
Journal:  Int J Epidemiol       Date:  1990       Impact factor: 7.196

Review 6.  Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers.

Authors:  Hisayuki Shigematsu; Adi F Gazdar
Journal:  Int J Cancer       Date:  2006-01-15       Impact factor: 7.396

7.  A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25.

Authors:  Rayjean J Hung; James D McKay; Valerie Gaborieau; Paolo Boffetta; Mia Hashibe; David Zaridze; Anush Mukeria; Neonilia Szeszenia-Dabrowska; Jolanta Lissowska; Peter Rudnai; Eleonora Fabianova; Dana Mates; Vladimir Bencko; Lenka Foretova; Vladimir Janout; Chu Chen; Gary Goodman; John K Field; Triantafillos Liloglou; George Xinarianos; Adrian Cassidy; John McLaughlin; Geoffrey Liu; Steven Narod; Hans E Krokan; Frank Skorpen; Maiken Bratt Elvestad; Kristian Hveem; Lars Vatten; Jakob Linseisen; Françoise Clavel-Chapelon; Paolo Vineis; H Bas Bueno-de-Mesquita; Eiliv Lund; Carmen Martinez; Sheila Bingham; Torgny Rasmuson; Pierre Hainaut; Elio Riboli; Wolfgang Ahrens; Simone Benhamou; Pagona Lagiou; Dimitrios Trichopoulos; Ivana Holcátová; Franco Merletti; Kristina Kjaerheim; Antonio Agudo; Gary Macfarlane; Renato Talamini; Lorenzo Simonato; Ray Lowry; David I Conway; Ariana Znaor; Claire Healy; Diana Zelenika; Anne Boland; Marc Delepine; Mario Foglio; Doris Lechner; Fumihiko Matsuda; Helene Blanche; Ivo Gut; Simon Heath; Mark Lathrop; Paul Brennan
Journal:  Nature       Date:  2008-04-03       Impact factor: 49.962

8.  EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.

Authors:  William Pao; Vincent Miller; Maureen Zakowski; Jennifer Doherty; Katerina Politi; Inderpal Sarkaria; Bhuvanesh Singh; Robert Heelan; Valerie Rusch; Lucinda Fulton; Elaine Mardis; Doris Kupfer; Richard Wilson; Mark Kris; Harold Varmus
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-25       Impact factor: 11.205

9.  Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.

Authors:  William Pao; Vincent A Miller; Katerina A Politi; Gregory J Riely; Romel Somwar; Maureen F Zakowski; Mark G Kris; Harold Varmus
Journal:  PLoS Med       Date:  2005-02-22       Impact factor: 11.069

10.  The feasibility of online genetic testing for lung cancer susceptibility: uptake of a web-based protocol and decision outcomes.

Authors:  Suzanne C O'Neill; Della Brown White; Saskia C Sanderson; Isaac M Lipkus; Gerold Bepler; Lori A Bastian; Colleen M McBride
Journal:  Genet Med       Date:  2008-02       Impact factor: 8.822

View more
  37 in total

1.  Quantitative assessment of the influence of common variations (rs8034191 and rs1051730) at 15q25 and lung cancer risk.

Authors:  Bin Hu; Ying Huang; Rong-huan Yu; Hong-ju Mao; Chao Guan; Jing Zhao
Journal:  Tumour Biol       Date:  2013-11-20

2.  A patient with metastatic lung adenocarcinoma harboring concurrent EGFR L858R, EGFR germline T790M, and PIK3CA mutations: the challenge of interpreting results of comprehensive mutational testing in lung cancer.

Authors:  Philip E Lammers; Christine M Lovly; Leora Horn
Journal:  J Natl Compr Canc Netw       Date:  2014-01       Impact factor: 11.908

Review 3.  Germline mutations predisposing to non-small cell lung cancer.

Authors:  Gerald H Clamon; Aaron D Bossler; Taher Abu Hejleh; Muhammad Furqan
Journal:  Fam Cancer       Date:  2015-09       Impact factor: 2.375

4.  Hereditary lung cancer syndrome targets never smokers with germline EGFR gene T790M mutations.

Authors:  Adi Gazdar; Linda Robinson; Dwight Oliver; Chao Xing; William D Travis; Junichi Soh; Shinichi Toyooka; Lori Watumull; Yang Xie; Kemp Kernstine; Joan H Schiller
Journal:  J Thorac Oncol       Date:  2014-04       Impact factor: 15.609

5.  Family history of lung cancer in never smokers with non-small-cell lung cancer and its association with tumors harboring EGFR mutations.

Authors:  Elizabeth M Gaughan; Sarah K Cryer; Beow Y Yeap; David M Jackman; Daniel B Costa
Journal:  Lung Cancer       Date:  2012-12-27       Impact factor: 5.705

6.  Concurrent molecular alterations in tumors with germ line epidermal growth factor receptor T790M mutations.

Authors:  Anish Thomas; Liqiang Xi; Corey A Carter; Arun Rajan; Sean Khozin; Eva Szabo; Phillip A Dennis; Giuseppe Giaccone; Mark Raffeld
Journal:  Clin Lung Cancer       Date:  2013-03-26       Impact factor: 4.785

Review 7.  Molecular pathways: resistance to kinase inhibitors and implications for therapeutic strategies.

Authors:  Christine M Lovly; Alice T Shaw
Journal:  Clin Cancer Res       Date:  2014-05-01       Impact factor: 12.531

8.  Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation.

Authors:  Geoffrey R Oxnard; Maria E Arcila; Camelia S Sima; Gregory J Riely; Juliann Chmielecki; Mark G Kris; William Pao; Marc Ladanyi; Vincent A Miller
Journal:  Clin Cancer Res       Date:  2010-12-06       Impact factor: 12.531

Review 9.  Mechanisms of resistance to EGFR targeted therapies.

Authors:  Gorjan Hrustanovic; Bianca J Lee; Trever G Bivona
Journal:  Cancer Biol Ther       Date:  2013-01-28       Impact factor: 4.742

Review 10.  Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease.

Authors:  Kadoaki Ohashi; Yosef E Maruvka; Franziska Michor; William Pao
Journal:  J Clin Oncol       Date:  2013-02-11       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.